Glass House Brands GLAS
NYSE GLAS
$9.39 -0.31 (-3.20%)
At close: Aug 20, 2026 · 12:47 PM UTC

Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026)

Glass House Brands (GLAS) posted quarterly Total Non-Current Liabilities of $111.9 million for Q1 2026, little changed year-over-year from $111.8 million in Q1 2025, and up 5.08% quarter-over-quarter from $106.5 million in Q3 2025.

Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Total Non-Current Liabilities for 7 consecutive years, with $111.9 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities changed 0.09% year-over-year to $111.9 million; the TTM figure through Mar 2026 stood at $111.9 million (changed 0.09% YoY), while the FY2024 annual figure was $234000.0, down 1.68% from the prior year.
  • Total Non-Current Liabilities climbed to $111.9 million in Q1 2026 per GLAS's latest filing, from $106.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $6314.3 billion in Q2 2022 and bottomed at -$19099.6 billion in Q2 2023.
  • Historically, Total Non-Current Liabilities has averaged -$799.0 billion across 5 years, with a median of $112.9 million in 2025.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 508.06% — and 2023, when it sank 402.48%.
  • Glass House Brands' Total Non-Current Liabilities stood at $241373.0 in 2022, then dropped by 1.4% to $238000.0 in 2023, then fell by 1.68% to $234000.0 in 2024, then surged by 45396.15% to $106.5 million in 2025, then climbed by 5.08% to $111.9 million in 2026.
  • Business Quant data shows GLAS's Total Non-Current Liabilities at $111.9 million in Q1 2026, $106.5 million in Q3 2025, and $114.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 43.98 Bn 43.02 Bn - -13.28 Bn
2 Teva Pharmaceutical Industries 43.28 Bn 39.62 Bn 2.15 Bn 16.45 Bn
3 Zoetis 31.79 Bn 30.11 Bn 1.05 Bn 11.64 Bn
4 Takeda Pharmaceutical 28.69 Bn 22.89 Bn 5.10 Bn 33.50 Bn
5 United Therapeutics 22.25 Bn 19.58 Bn 683.80 Mn 607.80 Mn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn 18.76 Bn
7 Neurocrine Biosciences 15.58 Bn 15.19 Bn 935.80 Mn 1.37 Bn
8 Elanco Animal Health 11.87 Bn 11.34 Bn 798.00 Mn 6.42 Bn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - 334.00 Mn
10 Glass House Brands 825.81 Mn 807.26 Mn 15.77 Mn 109.72 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 111.87 Mn
Sep 30, 2025 106.46 Mn
Jun 30, 2025 114.01 Mn
Mar 31, 2025 111.77 Mn
Dec 31, 2024 234,000.00
Sep 30, 2024 142.81 Mn
Jun 30, 2024 167.07 Mn
Mar 31, 2024 160.87 Mn
Dec 31, 2023 238,000.00
Sep 30, 2023 152.08 Mn
Jun 30, 2023 -19,099.58 Bn
Mar 31, 2023 132.95 Mn
Dec 31, 2022 241,373.00
Sep 30, 2022 160.98 Mn
Jun 30, 2022 6,314.33 Bn
Mar 31, 2022 65.28 Mn
Dec 31, 2021 104.20 Mn
Sep 30, 2021 26.47 Mn
Mar 31, 2021 479.73 Mn
Dec 31, 2020 456.33 Mn